Commonwealth Equity Services LLC Buys 29,770 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

Commonwealth Equity Services LLC lifted its stake in shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) by 24.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 149,962 shares of the company’s stock after acquiring an additional 29,770 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Mind Medicine (MindMed) were worth $361,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Eudaimonia Partners LLC boosted its stake in shares of Mind Medicine (MindMed) by 33.3% during the 3rd quarter. Eudaimonia Partners LLC now owns 20,000 shares of the company’s stock worth $47,000 after acquiring an additional 5,000 shares in the last quarter. Strs Ohio boosted its stake in Mind Medicine (MindMed) by 6.8% during the 3rd quarter. Strs Ohio now owns 79,800 shares of the company’s stock valued at $185,000 after purchasing an additional 5,100 shares during the period. Investment Advisory Services Inc. TX ADV bought a new stake in Mind Medicine (MindMed) during the 2nd quarter valued at approximately $35,000. IPG Investment Advisors LLC bought a new stake in Mind Medicine (MindMed) during the 2nd quarter valued at approximately $36,000. Finally, NorthRock Partners LLC bought a new stake in Mind Medicine (MindMed) during the 2nd quarter valued at approximately $37,000. Institutional investors own 10.66% of the company’s stock.

Mind Medicine (MindMed) stock opened at 1.12 on Friday. The business has a 50 day moving average price of 1.80 and a two-hundred day moving average price of 2.43. The stock has a market cap of $467.39 million and a price-to-earnings ratio of -5.60. Mind Medicine has a 12 month low of 1.07 and a 12 month high of 5.77.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings results on Friday, November 12th. The company reported -0.06 EPS for the quarter, missing the consensus estimate of -0.03 by -0.03. As a group, sell-side analysts expect that Mind Medicine will post -0.24 earnings per share for the current year.

Separately, Zacks Investment Research downgraded Mind Medicine (MindMed) from a “hold” rating to a “sell” rating in a research note on Thursday, November 25th.

About Mind Medicine (MindMed)

Mind Medicine (MindMed), Inc operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L.

Further Reading: The mechanics of the bid-ask spread in trading

Want to see what other hedge funds are holding MNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mind Medicine (MindMed) Inc. (NASDAQ:MNMD).

Institutional Ownership by Quarter for Mind Medicine (MindMed) (NASDAQ:MNMD)

Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.